Compounded retatrutide can be dangerous to use because it carries unknown risks, including potentially inconsistent doses and no regulatory oversight
Elevated levels of triglycerides and free fatty acids in circulation are major factors driving lipid accumulation in the liver, leading to metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis
One example escalation schedule observed in Phase 2 obesity trials proceeded broadly as follows: Weeks 14: 2 mg once weekly (initiation phase) Weeks 58: 4 mg once weekly Weeks 912: 8 mg once weekly Weeks 13 onwards: Up to 12 mg once weekly (the maximum dose explored in Phase 2 trials) This is an illustrative example only
Retrieved from Papatriantafyllou, E., Efthymiou, D., Zoumbaneas, E., et al
Retatrutide: Weight loss potential Since retatrutide isnt available yet, the best way to understand its potential is through clinical trials
Over time, this shifts liver metabolism away from fat storage toward fat utilization, gradually depleting accumulated triglycerides within liver cells
:max_bytes(150000):strip_icc()/VWH-GettyImages-2158519129-372ed708fbbb4c6e9f472a8218cd52ee.jpg)
